Safety and potential toxicity evaluation of the CR2/3–CAR-TVSVtreatment. (A) Body weight of NCG mice bearing U87 intracranial xenografts were measured every 3 days (n = 4 mice). (B) The inflammatory cytokine (TNFα and IL-6) levels in the serum of mice 9 days after the indicated treatments (n = 4 mice). (C)In vivo biosafety analysis of LDH, aspartate aminotransferase (AST), and alanine transaminase (ALT) in the mice 9 days after the indicated treatment. (D) H&E staining of vital tissues, including kidney, intestine, liver, and spleen. A representative experiment is shown, repeated once. Data represent the mean ± SD from one representative from two independent experiments (A and B). Statistics by two-way ANOVA (A) and one-way ANOVA (B and C). *, P < 0.05; **, P < 0.01; N.S., no significance.
Figure S5.

Safety and potential toxicity evaluation of the CR2/3–CAR-T VSV treatment. (A) Body weight of NCG mice bearing U87 intracranial xenografts were measured every 3 days (n = 4 mice). (B) The inflammatory cytokine (TNFα and IL-6) levels in the serum of mice 9 days after the indicated treatments (n = 4 mice). (C)In vivo biosafety analysis of LDH, aspartate aminotransferase (AST), and alanine transaminase (ALT) in the mice 9 days after the indicated treatment. (D) H&E staining of vital tissues, including kidney, intestine, liver, and spleen. A representative experiment is shown, repeated once. Data represent the mean ± SD from one representative from two independent experiments (A and B). Statistics by two-way ANOVA (A) and one-way ANOVA (B and C). *, P < 0.05; **, P < 0.01; N.S., no significance.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal